Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX · NASDAQ Global Market
-$0.02 today
Vol 0.10M · Avg 0.34M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-196.8%
avg -379.0%
ROIC
-162.4%
avg -174.6%
ROA
-165.8%
avg -312.0%
Analysis
ROIC is currently the strongest return metric at -162.4% versus its period average of -174.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Lisa L. Bollinger | Chief Medical Officer | $292,188.00 | — | 62 | — | — |
G. Michael Landis | CFO & Director | $46,667.00 | — | 60 | — | — |
Alex Yang | CEO & Chair of Board | — | — | 56 | — | — |
Andrew John | Chief Investment Officer | — | — | 53 | — | — |
Shrijay Vijayan | Chief Scientific & Business Development Officer | — | — | 58 | — | — |
Wuxin Zhu | Chief Chemistry, Manufacturing & Controls Officer | — | — | 46 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Jade Biosciences, Inc.
NASDAQ:JBIO
$551.66M
Crescent Biopharma, Inc.
NASDAQ:CBIO
$487.18M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$293.54M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$242.49M
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$135.37M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$89.77M
Kezar Life Sciences, Inc.
KZR
$53.86M
Pelthos Therapeutics Inc.
PTHS
$17.96M
NextCure, Inc.
NXTC
$5.44M
HCW Biologics Inc.
HCWB
$2.22M
Who manages PLYX?
Polaryx Therapeutics, Inc. Common Stock (PLYX) lists 6 active executives. The top listed executive is Alex Yang, CEO & Chair of Board.
Explore More
Continue the stock analysis
Jump to another research area for this company.